Brian K Halak - Net Worth and Insider Trading

Brian K Halak Net Worth

The estimated net worth of Brian K Halak is at least $181 Million dollars as of 2024-11-06. Brian K Halak is the Director of Dicerna Pharmaceuticals Inc and owns about 2,605,685 shares of Dicerna Pharmaceuticals Inc (DRNA) stock worth over $100 Million. Brian K Halak is the 10% Owner of Achillion Pharmaceuticals Inc and owns about 8,032,129 shares of Achillion Pharmaceuticals Inc (ACHN) stock worth over $54 Million. Brian K Halak is also the 10% Owner of Zogenix Inc and owns about 824,073 shares of Zogenix Inc (ZGNX) stock worth over $22 Million. Besides these, Brian K Halak also holds Esperion Therapeutics Inc (ESPR) , Ocera Therapeutics Inc (OCRX) , Clovis Oncology Inc (CLVSQ) , Orexigen Therapeutics Inc (OREXQ) . Details can be seen in Brian K Halak's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Brian K Halak has not made any transactions after 2018-11-06 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Brian K Halak

To

Brian K Halak Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Brian K Halak owns 28 companies in total, including Alimera Sciences Inc (ALIM) , Obalon Therapeutics Inc (OBLN) , and Adynxx Inc (ADYX) among others .

Click here to see the complete history of Brian K Halak’s form 4 insider trades.

Insider Ownership Summary of Brian K Halak

Ticker Comapny Transaction Date Type of Owner
ALIM Alimera Sciences Inc 2010-04-21 director
OBLN Obalon Therapeutics Inc 2019-08-06 10 percent owner
ADYX Adynxx Inc 2019-05-03 10 percent owner
LIMIT LIMIT 2018-11-06 director
LIMIT LIMIT 2018-08-21 10 percent owner
LIMIT LIMIT 2017-12-11 10 percent owner
LIMIT LIMIT 2016-11-01 10 percent owner
LIMIT LIMIT 2013-09-24 10 percent owner
LIMIT LIMIT 2016-03-02 10 percent owner
LIMIT LIMIT 2015-06-24 10 percent owner
LIMIT LIMIT 2015-05-06 10 percent owner
LIMIT LIMIT 2013-07-01 10 percent owner
LIMIT LIMIT 2014-11-19 10 percent owner
LIMIT LIMIT 2014-10-15 10 percent owner
LIMIT LIMIT 2013-10-29 10 percent owner
LIMIT LIMIT 2014-08-12 10 percent owner
LIMIT LIMIT 2014-07-31 10 percent owner
LIMIT LIMIT 2014-05-01 10 percent owner
LIMIT LIMIT 2014-03-17 10 percent owner
LIMIT LIMIT 2013-11-13 10 percent owner
LIMIT LIMIT 2011-11-21 10 percent owner
LIMIT LIMIT 2013-01-18 10 percent owner
LIMIT LIMIT 2013-01-14 10 percent owner
LIMIT LIMIT 2011-12-22 10 percent owner
LIMIT LIMIT 2011-09-16 10 percent owner
LIMIT LIMIT 2006-04-12 director
LIMIT LIMIT 2006-05-09 10 percent owner
LIMIT LIMIT 2016-10-05 10 percent owner

Brian K Halak Latest Holdings Summary

Brian K Halak currently owns a total of 7 stocks. Among these stocks, Brian K Halak owns 2,605,685 shares of Dicerna Pharmaceuticals Inc (DRNA) as of November 6, 2018, with a value of $100 Million and a weighting of 55.08%. Brian K Halak owns 8,032,129 shares of Achillion Pharmaceuticals Inc (ACHN) as of August 20, 2010, with a value of $54 Million and a weighting of 30.03%. Brian K Halak also owns 824,073 shares of Zogenix Inc (ZGNX) as of November 29, 2010, with a value of $22 Million and a weighting of 12.16%. The other 4 stocks Esperion Therapeutics Inc (ESPR) , Ocera Therapeutics Inc (OCRX) , Clovis Oncology Inc (CLVSQ) , Orexigen Therapeutics Inc (OREXQ) have a combined weighting of 2.73% among all his current holdings.

Latest Holdings of Brian K Halak

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
DRNA Dicerna Pharmaceuticals Inc 2018-11-06 2,605,685 38.22 99,589,281
ACHN Achillion Pharmaceuticals Inc 2010-08-20 8,032,129 6.76 54,297,192
ZGNX Zogenix Inc 2010-11-29 824,073 26.68 21,986,268
ESPR Esperion Therapeutics Inc 2013-07-01 2,102,188 2.12 4,456,639
OCRX Ocera Therapeutics Inc 2013-07-15 246,386 1.79 441,031
CLVSQ Clovis Oncology Inc 2011-11-21 3,041,950 0.02 45,629
OREXQ Orexigen Therapeutics Inc 2011-12-22 301,806 0.01 1,600

Holding Weightings of Brian K Halak


Brian K Halak Form 4 Trading Tracker

According to the SEC Form 4 filings, Brian K Halak has made a total of 0 transactions in Dicerna Pharmaceuticals Inc (DRNA) over the past 5 years. The most-recent trade in Dicerna Pharmaceuticals Inc is the sale of 335,000 shares on November 6, 2018, which brought Brian K Halak around $4 Million.

According to the SEC Form 4 filings, Brian K Halak has made a total of 0 transactions in Achillion Pharmaceuticals Inc (ACHN) over the past 5 years. The most-recent trade in Achillion Pharmaceuticals Inc is the sale of 0 shares on August 20, 2010, which brought Brian K Halak around $0.

According to the SEC Form 4 filings, Brian K Halak has made a total of 0 transactions in Zogenix Inc (ZGNX) over the past 5 years. The most-recent trade in Zogenix Inc is the acquisition of 293,750 shares on November 29, 2010, which cost Brian K Halak around $9 Million.

More details on Brian K Halak's insider transactions can be found in the Insider Trading History of Brian K Halak table.

Insider Trading History of Brian K Halak

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Brian K Halak Trading Performance

GuruFocus tracks the stock performance after each of Brian K Halak's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Brian K Halak is 15.68%. GuruFocus also compares Brian K Halak's trading performance to market benchmark return within the same time period. The performance of stocks bought by Brian K Halak within 3 months outperforms 5 times out of 19 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Brian K Halak's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Brian K Halak

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
6 out of 19 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 14.92 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 11.38 LIMIT LIMIT LIMIT LIMIT LIMIT

Brian K Halak Ownership Network

Ownership Network List of Brian K Halak

No Data

Ownership Network Relation of Brian K Halak

Insider Network Chart

Brian K Halak Owned Company Details

What does Alimera Sciences Inc do?

Who are the key executives at Alimera Sciences Inc?

Brian K Halak is the director of Alimera Sciences Inc. Other key executives at Alimera Sciences Inc include 10 percent owner Caligan Partners Lp , other: Chairman Emeritus C. Daniel Myers , and 10 percent owner David Edward Johnson .

Alimera Sciences Inc (ALIM) Insider Trades Summary

Over the past 18 months, Brian K Halak made no insider transaction in Alimera Sciences Inc (ALIM). Other recent insider transactions involving Alimera Sciences Inc (ALIM) include a net sale of 0 shares made by Caligan Partners Lp , and a net purchase of 1,401,901 shares made by Adam Morgan .

In summary, during the past 3 months, insiders sold 0 shares of Alimera Sciences Inc (ALIM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 579,000 shares of Alimera Sciences Inc (ALIM) were sold and 1,980,901 shares were bought by its insiders, resulting in a net purchase of 1,401,901 shares.

Alimera Sciences Inc (ALIM)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Alimera Sciences Inc Insider Transactions

No Available Data

Brian K Halak Mailing Address

Above is the net worth, insider trading, and ownership report for Brian K Halak. You might contact Brian K Halak via mailing address: C/o Domain Associates, One Palmer Square, Princeton Nj 08542.